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Recently, we showed that truncation of the X-linked cyclin-dependent kinase–like 5 (CDKL5/STK9) gene caused
mental retardation and severe neurological symptoms in two female patients. Here, we report that de novo missense
mutations in CDKL5 are associated with a severe phenotype of early-onset infantile spasms and clinical features
that overlap those of other neurodevelopmental disorders, such as Rett syndrome and Angelman syndrome. The
mutations are located within the protein kinase domain and affect highly conserved amino acids; this strongly
suggests that impaired CDKL5 catalytic activity plays an important role in the pathogenesis of this neurodevel-
opmental disorder. In view of the overlapping phenotypic spectrum of CDKL5 and MECP2 mutations, it is tempting
to speculate that these two genes play a role in a common pathogenic process.
In our recent study of two unrelated females with bal-
anced X;autosome translocations, we showed that trun-
cation of the cyclin-dependent kinase–like 5 (CDKL5/
STK9) gene causes a severe phenotype of early-onset
infantile spasms, global developmental arrest, and pro-
found mental retardation (Kalscheuer et al. 2003). The
phenotypes in these patients are reminiscent of the neo-
natal-onset encephalopathy seen in several patients with
a severe form of atypical Rett syndrome (RTT [MIM
312750]) (Schanen et al. 1998; Villard et al. 2000; Zeev
et al. 2002). RTT is a progressive neurodevelopmental
disorder that affects almost exclusively girls. The classic
form of RTT is characterized by apparently normal de-
velopment, followed by neurological developmental ar-
rest and regression (Hagberg et al. 1983). The increase
in cognitive and motor impairments may continue for
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many years before reaching a plateau; this progression
typically leads to profound mental retardation. Patients
with a milder RTT variant may retain some speech and
motor functions, whereas those with more severe forms
develop the disease shortly after birth and often have
congenital hypotonia and infantile spasms (Hanefeld
1985; Goutieres and Aicardi 1986; Hagberg and Skjeldal
1994). In ∼80% of patients with typical RTT, amutation
has been found in the methyl-CpG–binding protein 2
(MECP2) gene, but only 20%–40% of patients with
atypical RTT have been shown to carry a mutation in
this gene (Buyse et al. 2000; Cheadle et al. 2000; Bour-
don et al. 2001). These ﬁndings indicate the possible
presence of another, as-yet undetected gene on the X
chromosome that may play a role in atypical RTT. It is
noteworthy that the phenotypic spectrum of MECP2
mutations is diverse, including autism (Lam et al. 2000;
Carney et al. 2003), Angelman syndrome–like features
in females (Imessaoudene et al. 2001;Watson et al. 2001),
neonatal-onset encephalopathy (Schanen et al. 1998; Vil-
lard et al. 2000), and nonsyndromic mental retardation
in males (Couvert et al. 2001; Yntema et al. 2002).
We have screened the entire CDKL5 ORF for muta-
tions in a cohort of 32 patients (25 females and 7 males)
who had been diagnosed with RTT syndrome or a variant
of RTT and in whom no MECP2 mutation had been
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Figure 1 CDKL5 mutation c.455GrT (p.C152F) in family 1. A, Pedigree for family 1. B, Patient II:2 at the age of 6.5 years. C, Sequence
chromatograms from family members I:1, I:2, and the proband (II:2). The affected nucleotide is indicated by a blackened arrow.
identiﬁed. All blood samples were obtained after pro-
vision of informed consent. PCR primers and denaturing
high-performance liquid chromatography (DHPLC)
conditions used for mutation analysis are available on
request.
Apart from two putative mutations described be-
low, we detected four polymorphisms in CDKL5. A
c.2372ArC (p.Q791P) change was present in ﬁve pa-
tients and in 3 of 96 control X chromosomes. Three
other nucleotide exchanges—IVS417ArG, c.3003CrT
(p.H1001H), and c.3084GrA (p.T1028T)—formed a
rare conserved haplotype that was found in one patient
and in 2 of 267 control X chromosomes from Caucasian
individuals (data not shown).
In the patient from family 1 (ﬁg. 1A and 1B), we
found a c.455GrT nucleotide change (GenBank ac-
cession number NM_003159) in exon 7 that results in
a cysteine-to-phenylalanine substitution at position 152
(p.C152F) of the CDKL5 protein (GenBank accession
number NP_003150) (ﬁg. 1C). The corresponding se-
quence of the parents’ DNA did not show this change
(ﬁg. 1C), which strongly suggests that this change is a
de novo mutation.
The patient is a female who was born by spontaneous
delivery after an uneventful pregnancy. Her parents are
healthy and nonconsanguineous, and she has a healthy
sister. Her birth weight was 3,500 g, and her length was
53 cm. The neonatal period was normal. At 5 wk of age,
she had Blitz-Nick-Salaam–like seizures. At 3 mo of age,
her electroencephalogram (EEG) was normal. Therapies
with vigabatrin, phenobarbital, and carbamacepine had
no effect. After implantation of a vagus-nerve stimulator
at the age of 4.5 years, the parents reported that seizures
occurred less frequently. At reevaluation at 5 years of age,
the patient weighed 13.9 kg (3rd percentile), her length
was 115 cm (75th percentile), and her head circumference
was 48.8 cm (10th percentile). EEG showed abnormal
and generalized theta rhythm, but neither focal distur-
bances nor any patterns typical of epilepsy were observed.
She was very hypotonic, was unable to crawl, and could
not sit without support. She understood simple words but
could not speak. The patient had initially been diagnosed
with Angelman syndrome or atypical RTT syndrome.
Methylation analysis of locus D15S63 was normal, and
a mutation search in UBE3A and MECP2 was negative.
In the index patient from family 2 (ﬁg. 2A and 2B),
we found a c.525ArT nucleotide change in exon 8 (ﬁg.
2C), which changes an arginine to a serine at position
175 (p.R175S) of the CDKL5 protein. The patient is an
MZ twin born to healthy, unrelated parents. Her birth
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Figure 2 CDKL5 mutation c.525ArT (p.R175S) in family 2. A, Pedigree for family 2. The index patient (II:2) is indicated by a blackened
arrow. B, Affected twin sisters (II:2 and II:3) at the age of 41 years. Note stereotypic hand movements of the proband (II:2). C, Sequence
chromatograms from the family members. From left to right: father (I:1), mother (I:2), unaffected sister (II:1), the index patient (II:2), and her
MZ sister (II:3). The affected nucleotide is indicated by a blackened arrow.
weight was 3,420 g, and the pregnancy was normal. The
mother was being treated for hypothyroidism and had
had two previous miscarriages. At 2 mo of age, the pa-
tient developed infantile spasms, which disappeared at
6 mo of age, but, later in life, absence seizures were
repeatedly observed. During infancy, severe psychomo-
tor retardation was noticed (Bayley mental scale: 2 mo
at the age of 12 years). She was able to sit without support
at 3 years of age, and, at 10 years of age, she was able
to walk a few steps with support. She never developed
speech. There was general hypotonia, mild ataxia, and
stereotypic movements of the hands. Intentional activity
or eye contact was absent. Mood swings were noticed,
with alternating bursts of crying and laughter, as well as
episodes of hyperventilation.On follow-up, shedeveloped
progressive sinistro-convex thoraco-lumbal kyphosco-
liosis and hypertonia leading to ﬂexion contractures of
the arms. Growth parameters for height, length, and head
circumference are within the 5th–25th percentile. Her
adult head circumference is 54.5 cm. Now aged 41 years,
she is wheelchair bound and still presents with stereotypic
hand movements, mood swings, and episodes of hyper-
ventilation. Additional examinations, including brain
scan, ophthalmological and hearing tests, routine blood
analyses, thyroid hormone tests, metabolic screening, and
karyotype analysis, were normal. Repeated EEG analyses
exhibited diffuse slow theta activity, but typical epilepti-
form abnormalities were not observed. Screening forpoint
mutations and deletions in theMECP2 genewas negative.
The proband’s MZ twin sister exhibits a similar phe-
notype (ﬁg. 2B); PCR ampliﬁcation and sequence anal-
ysis of exon 8 conﬁrmed the presence of the same mu-
tation (ﬁg. 2C). Like her twin sister, she developed in-
fantile spasms at 10 wk of age, which disappeared at 6
mo of age. During infancy, severe psychomotor retar-
dation was noticed, although the impairment of her mo-
tor development was less severe than that in her sister.
Her walk is characterized by atactic movements and im-
paired coordination, but, at 8 years of age, she was able
to walk alone. Like her sister, she exhibited stereotypic
movements of the hands, made little eye contact, and
demonstrated essentially no interaction with her environ-
ment. Mood swings and hyperventilation episodes were
also present. On further follow-up, she presented with S-
shaped dorso-lumbal scoliosis and hypertonia, as well as
ﬂexion contractures of the arms, knees, and Achilles ten-
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Figure 3 Multiple sequence alignment of human CDKL5 with its vertebrate orthologs and with closely related human protein kinases
CDKL1, CDKL2, and CDKL3 in the region of the kinase subdomains VII and VIII (see the ClustalW Web site). In the alignment, the residues
that differ from the consensus sequence are shown with a gray background. The invariant DFG motif in subdomain VII and the substrate
recognition sequence YVATRWYR in subdomain VIII are boxed. Affected amino acids are indicated by a blackened arrow. Amino acid
substitutions are shown above the alignment.
dons. Growth parameters for height, length, and head
circumference are within the normal range (5th–15th
percentile), and her adult head circumference is 54 cm.
Now, at the age of 41 years, she is still able to walk a
few steps with support. Both sisters also exhibit abdom-
inal distention because of excessive air swallowing.
The mutation identiﬁed in the twin sisters was present
neither in their healthy parents nor in an unaffected sis-
ter, which suggests that it occurred de novo.
The predicted CDKL5 protein contains a conserved
serine/threonine kinase domain in the N-terminus. Se-
quence comparison revealed that its kinase domain shares
high homology with p42 KKIALRE (CDKL1) (Yen et al.
1995), p53 KKIAMRE (CDKL2) (Taglienti et al. 1996),
and NKIAMRE (CDKL3) (Midmer et al. 1999), which
are members of the protein kinase subfamily with both
mitogen-activated protein kinase (MAPK) and cyclin-de-
pendent kinase (CDK) features. The amino acids mutated
in the patients lie in critical protein domains that are im-
portant for proper kinase function. The Cys152 amino
acid in kinase subdomain VII is immediately N-terminal
to the conserved Asp-Phe-Gly motif (ﬁg. 3), one of the
kinase signatures involved in phosphotransfer (Hanks and
Hunter 1995). Although, in other unrelated protein ki-
nases, other small amino acids—such as alanine, glycine,
serine, or threonine—may be found at this position, none
of the protein kinases present in the GenBank database
contains a phenylalanine residue here (see BLAST Web
site). The substitution of a cysteine with a phenylalanine
residue would likely alter the proper orientation of the
adjacent Asp-Phe-Gly motif and therefore would most
likely impair the catalytic activity of the protein. The other
mutated amino acid, Arg175, lies within kinase subdo-
main VIII (ﬁg. 3), which is important for substrate rec-
ognition (Hanks andHunter 1995). The sequence context
of this amino acid (YVATRWYR) is highly conserved
in proline-directed protein kinase subfamilies, such as
MAPKs and CDKs, and is required for the selectivity
toward substrates containing a proline at the P1 po-
sition, relative to the phosphate acceptor (Russo et al.
1996; Canagarajah et al. 1997). Exchange of a positively
charged arginine for an uncharged serine would likely
inﬂuence substrate-binding speciﬁcity.
Taken together, several lines of evidence argue for the
pathogenic nature of these missensemutations. First, both
mutations most likely occurred de novo. Second, they
both lie within critical regions of the serine/threonine ki-
nase domain and therefore most likely have deleterious
effects on CDKL5 kinase activity. Third, the mutated
amino acids are conserved in mouse and Fugu rubripes
Cdkl5 orthologs and are also present in other closely re-
lated protein kinases, including CDKL1, CDKL2, and
CDKL3 (ﬁg. 3). Finally, neither of the missense mutations
was found in 427 control X chromosomes.
Additional evidence that implicates CDKL5 in a severe
phenotype with strong similarities to the early-onset RTT
variant comes from the recent work of Weaving et al.
(2004 [in this issue]), who identiﬁed truncating frameshift
mutations in two unrelated families. Together, we have
found four different mutations, three of which involve the
protein kinase domain. These observations, together with
our previous identiﬁcation of disease-causing chromo-
some translocations that truncate CDKL5 (Kalscheuer et
al. 2003), suggest that mutations in CDKL5 are associ-
ated with a wide range of clinical features, which is also
the case for MECP2 mutations. The associated disorder
may be severe, with early-onset encephalopathy, as seen
in both translocation patients (Kalscheuer et al. 2003) as
well as in one male patient with a frameshift mutation
(Weaving et al. 2004 [in this issue]). These patients pre-
sented with infantile spasms, severe global developmental
delay, and profound intellectual impairment; they never
learned to speak, sit, or walk, and they never developed
visual or social response. At the other end of the spectrum
is the mild mental retardation with autistic features pre-
sent in one female twin with a frameshift mutation in
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CDKL5. She retains reasonable verbal skills and has no
obvious motor deﬁciencies (Weaving et al. 2004 [in this
issue]). The female patients described here and the two
female patients reported by Weaving et al. (2004 [in this
issue]) have intermediate phenotypes. All of them had an
apparently normal pre- and perinatal period but devel-
oped severe epileptic activity between 5 wk and 3 mo of
age, followed by psychomotor and behavioral develop-
ment delay, with or without a period of regression. On
examination, all of these affected girls exhibited motor
deﬁciency, autistic features, and mental retardation, as
well as absence of speech and of purposeful hand use.
The affected female patients described in this study did
not exhibit the regression period of classic RTT; in par-
ticular, in the patient from family 1, no symptoms related
to classic RTT, other than those mentioned above, were
present, probably because of her young age (6.5 years old
at present). However, the cluster of these clinical features
meets almost all of the criteria for the early-onset variant
of RTT (Goutieres and Aicardi 1986; Hagberg and Skjel-
dal 1994).
Our data, together with our previous results (Kal-
scheuer et al. 2003) and the ﬁndings of Weaving et al.
(2004 [in this issue]), indicate that a subset of patients
with a clinical picture resembling the early-onset RTT
variant or with a history of early-onset seizures, have
mutations in the CDKL5 gene. In the future, genotype-
phenotype correlations in additional patients with a var-
iant of RTT and a mutation in CDKL5 will probably
lead to a reclassiﬁcation of this subtype of RTT.
The phenotypic heterogeneity observed in female pa-
tients with a mutation in this gene may be due to variable
X-chromosome inactivation (XCI), since CDKL5 is sub-
ject to XCI. Consistent with this hypothesis, the most
severe phenotype, with early-onset encephalopathy, was
present in the females who carried the X;autosome trans-
locations, in which the normal X chromosome was com-
pletely inactivated (Kalscheuer et al. 2003). Likewise,
the hemizygous male with a frameshift mutation was
severely affected (Weaving et al. 2004 [in this issue]). In
females, expression of the wild-type allele in at least a
portion of the cells may mitigate the clinical manifes-
tations. Indeed, a normal XCI pattern was found in the
MZ twins in family 2 (data not shown), and a slightly
skewed XCI pattern that favored expression of the nor-
mal allele was seen in one female patient reported by
Weaving et al. (2004 [in this issue]). On the other hand,
the twin sisters described by Weaving et al. (2004 [in
this issue]) exhibited completely different clinical fea-
tures from each other but both had a similar XCI pattern
in cells from peripheral blood. In this case, the XCI pat-
tern in blood leukocytes may not reﬂect the XCI patterns
in the brain.
The phenotypic overlap between patients carrying
MECP2 and CDKL5 mutations may indicate that the
two genes play a role in a common pathogenic pathway.
MeCP2 is known to preferentially bind to methylated
CpG dinucleotides through its methyl-CpG–binding do-
main and to silence downstream target genes (Lewis et
al. 1992; Nan et al. 1998). Recently, it has been shown
that activation of target genes is associated with in-
creased phosphorylation of MeCP2 (Chen et al. 2003;
Stancheva et al. 2003). It is therefore tempting to spec-
ulate that CDKL5 may be involved in the regulation of
MeCP2 phosphorylation. Further characterization of the
CDKL5 signaling pathway, including its upstream ac-
tivators and downstream substrates, will help to eluci-
date the potential link between CDKL5 and MeCP2,
which will ultimately lead to elucidation of the patho-
genesis of this group of diseases.
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